The increased knowledge of the molecular mechanisms involved in thyroid cancer progression allowed the development of new therapeutic agents targeting specific pathways involved in disease progression, including RET, BRAF, RAS, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) receptor (VEGFR) [71,72,73]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.